top of page

Financing round for NordShield® successfully completed

Espoo, 10 September 2021 – Nordic BioTech Group Oy, marketed as NordShield® (“NordShield®”) has closed its latest financing round by securing over EUR 4.2 million to fund the commercialization of its technology and the further development thereof

The Finnish biotechnology company NordShield® has secured investments totaling more than EUR 4.2 million in its latest financing round completed on 30 August. In addition to securing further investment from existing shareholders, the round brought NordShield® new investors, including Transmeri Group, Veikko Laine Oy and Markku Kaloniemi. Swedbank in Finland acted as Sole Lead Manager to NordShield® in the transaction.

All NordShield® technology on the market is based on the unique layer formation of it. The technology creates a physical layer on the treated surface, which acts like an armor against bacteria and viruses but cannot be seen or felt. The newly raised capital allows NordShield® to respond to the rapidly growing global demand for its biodegradable technology and supports further research and development (R&D) thereof. Instead of widely used heavy metals, NordShield®’s core technology and efficacy are based on fractions of wood. These are obtained from side streams of the forest industry, making the whole lifecycle of the technology and its application environmentally sustainable. Currently, the technology is on the market for treating textiles, and as additive for disinfectants to achieve enhanced performance of them. NordShield® plans to strengthen its sales, technical services, marketing, and regulatory resources to accelerate market entries and further develop the technology for broader application opportunities.

“We are excited to welcome new investors on board and very grateful for the continued trust of our existing investors. The raised funds will expedite our vision of replacing heavy metals and other hazardous chemicals through our uniquely sustainable alternative. As a novel technology, we are paving the way to the best tomorrow and are thrilled to share this path with a growing group of people that is as strongly committed to sustainability as we are.”

- Kristoffer Ekman, CEO of NordShield®

“Our interest and motivation to invest in NordShield were twofold. The first reason was the truly disruptive sustainability of the technology and the broad opportunities of its application across industries. The second reason was strategic, as there are significant synergies and links between both our businesses. Combining all this with a strong, versatile, and committed team at NordShield gives us great confidence in our investment.”

- Kari Leimola, CEO of Transmeri Group

The highly scalable NordShield® technology as a unique combination of naturality and efficacy was born after more than a decade of R&D, resulting in three filed international patent families. The technology was developed to solve the environmental and health issues of conventional antimicrobial substances that are currently widely used in the industry such as silver, copper, and zinc. Heavy metals are highly antimicrobial, but at the same time, harmful to their users, accumulate in the environment and are associated with antibacterial resistance. The risks of using silver in antimicrobial treatments have been recognized already in 2014 by the European Commission and its non-food Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Governments, such as Sweden, imposing additional taxes and restrictions on hazardous substances clearly indicate a shift in the market. A new discipline has emerged to develop bio-based antimicrobial surfaces. NordShield® is uniquely positioned to offer a solution that provides an ultrathin protective film on the final product surface that works as a physical microbe inhibitor.

After commercialization in late 2020, the NordShield® technology is on the market with two product segments: NordShield® Fiber (textile treatment technology) and NordShield® Brilliant (technology to enhance the performance of disinfectants). To meet the growing demand for antimicrobial textiles, a market that in 2019 was valued at EUR 10 billion and estimated to reach over EUR 18 billion by 2027, NordShield Fiber contains two solutions to provide protective feature to achieve antiviral and antibacterial effect on the final product surface. One for medical textiles in the health care area (NordShield® Pathogen Barrier) and one for consumer textiles (NordShield BioLayr®).

NordShield® Pathogen Barrier is intended for textiles in the medical and healthcare areas. It is categorized as an essential component that enhances the quality and efficacy of textiles that are to be classified as medical devices under the Medical Device Regulation. NordShield® Pathogen Barrier treated textiles have proven over 99% efficacy against MVA, a surrogate virus for enveloped viruses (e.g. SARS, MERS, Hepatitis and influenza viruses), more than 99.9% efficacy against SARS-CoV-2, the virus causing Covid-19, as well as up to 99.999% efficacy against bacteria. NordShield® has secured an agreement with Swedish-based SHL Healthcare, one of the world’s leading contract manufacturers and suppliers of MedTech solutions for home, hospital, and long-term care use. NordShield® and SHL Healthcare will together develop the world’s first commercially produced and widely available medical textiles with natural-based antimicrobial technology, with the first products expected to be available on the market during 2021.

NordShield BioLayr® is an OEKO-TEX certified, novel technology for consumer and household textiles that has been dermatologically tested with the highest grade “excellent”. NordShield BioLayr® utilizes the unique physical layer that the core technology enables. This textile treatment technology is applied directly at the manufacturing site onto the textile.

The NordShield® Brilliant segment has brought a new kind of disinfectant to the market, giving an instant kill effect on microbes such as viruses and bacteria through ethanol, but as a unique selling point, it has proven its efficacy of blocking microbes and keeping its effect up to after seven weeks on the treated fabric surface (most recent test was conducted with SARS-CoV-2, the virus causing Covid-19, on textiles). NordShield® Brilliant technology can be applied e.g. to hands, textiles and surfaces for disinfection, as well as on shoes and performance gear to prevent bacteria and fungi responsible for odor, staining and deterioration. NordShield® Brilliant technology has been white-labeled and sold in France and Switzerland, with further distribution agreements under active negotiation globally.


About NordShield®

Nordic BioTech Group, branded as NordShield®, is the world-leading innovative biotechnology company in the field of developing new bio-based antimicrobial solutions. Founded in 2016 and headquartered in Espoo, Finland, NordShield® is disrupting the field of antimicrobial technology through a durable, wood-based alternative for antimicrobial surface protection utilized across applications and industries. NordShield® as a commercial technology was born after more than ten years of researching, developing, testing, verifying, certifying, and patenting. The result is a revolutionary technology with a unique combination of naturality, power, and efficacy. This scalable technology enables the strongest protection with the highest innovativeness - a creation as unique and powerful as nature and one that leaves nothing but goodness behind.

For more information, visit

Contact to NordShield®:

Emmi Kavander, Chief Communications Officer / NordShield®



This document may contain statements related to Nordic Biotech Group Oy’s future business and financial performance and future events or developments that may constitute forward-looking statements. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated status of any such statements. Nordic Biotech Group neither intends nor assumes any obligation to update or revise these statements in light of developments that differ from those anticipated. Nordic BioTech Group Oy and its affiliates are not liable for any decision made or action taken in conjunction with the information and/or statement in this document or for any related damage.

This document contains statements that are only applicable within the European Union, and this document is intended only for distribution within the European Union. Nordic BioTech Group Oy does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of any such statements and is not liable for any such statements.


bottom of page